Findings

What do systematic reviews say?

31 questions · 32 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 9.4%GRADE not reported 3 · 9.4%Very low 19 · 59.4%Low 2 · 6.3%Moderate 5 · 15.6%High 0 · 0%

Selective serotonin reuptake inhibitors vs placebo

Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Adverse events (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

PSG sleep outcomes (at 12 weeks) · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Dropout · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.81 [0.51, 1.3]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.05 [0.67, 1.64]
1 study · 14 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.46]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.24 [0.68, 2.24]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a continuous outcome · patients with cancer and depression

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 237 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 1.1
2 studies · 199 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
3 studies · 237 participants
Very low